Excluding skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the US and the second most common cause of cancer death among men. It is estimated that about one in six men in the US will be diagnosed with prostate cancer during their lifetime. The five-year survival is 100% when cancer is detected in stage I; therefore, early diagnosis and treatment is critical.

A new Webinar will review the current role of PSA biomarkers, strategies for increasing specificity of PSA testing, and offer expert advice for optimizing risk assessment protocols. The Webinar, which will take place Tuesday, July 12, at 12 PM CET, will outline early detection recommendations, explain the relevancy of PSA testing, review recent prostate cancer studies, and describe approaches for addressing specificity challenges associated with PSA testing.

Judd W. Moul, MD, FACS, professor and chief, division of urology, department of surgery, Duke University Medical Center, Durham, NC, will host the event.

To register, click here.